Article Sidebar
Main Article Content
Abstract
Background: Peripheral neuropathy is a common side effect of paclitaxel chemotherapy that can cause tingling, numbness, and pain in the hands and feet. Metformin, an antidiabetic drug, shows potential in preventing and managing paclitaxel chemotherapy-induced peripheral neuropathy. This review article aims to evaluate the efficacy of metformin in the prevention and management of peripheral neuropathy due to paclitaxel chemotherapy.
Methods: Electronic literature (PubMed, Scopus, Web of Science) was reviewed to find clinical studies examining the efficacy of metformin in the prevention and management of paclitaxel chemotherapy-induced peripheral neuropathy.
Results: Eight clinical studies with a total of 542 patients were evaluated. Metformin significantly reduced the risk of developing peripheral neuropathy compared with placebo (OR = 0.54; 95% CI: 0.32-0.91). Metformin significantly reduced neuropathy symptom scores compared with placebo (MD = -1.52; 95% CI: -2.43 to -0.61). Metformin significantly improved patients' quality of life compared with placebo (MD = 0.48; 95% CI: 0.17-0.79).
Conclusion: Metformin shows promising efficacy in the prevention and management of paclitaxel chemotherapy-induced peripheral neuropathy.
Keywords
Article Details
As our aim is to disseminate original research article, hence the publishing right is a necessary one. The publishing right is needed in order to reach the agreement between the author and publisher. As the journal is fully open access, the authors will sign an exclusive license agreement.
The authors have the right to:
- Share their article in the same ways permitted to third parties under the relevant user license.
- Retain copyright, patent, trademark and other intellectual property rights including research data.
- Proper attribution and credit for the published work.
For the open access article, the publisher is granted to the following right.
- The non-exclusive right to publish the article and grant right to others.
- For the published article, the publisher applied for the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
